Isoniazida Labesfal (Isoniazid)

Isoniazid inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. By blocking the enzyme InhA, it prevents cell‑wall formation, leading to bacterial death, particularly against actively replicating Mycobacterium tuberculosis organisms.

The dosage of Isoniazida Labesfal is determined by the prescribing clinician based on patient weight, age, disease status, and renal or hepatic function. Healthcare providers follow national guidelines to set an appropriate daily dose and treatment duration.

Isoniazid is classified as a pregnancy‑category drug where benefits may outweigh potential risks. It can be used when the mother has active or latent TB, but clinicians usually prescribe pyridoxine to reduce neuropathy risk. Breastfeeding is generally considered acceptable under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoniazid is a first‑line agent with high early bactericidal activity, often combined with rifampicin, pyrazinamide and ethambutol. Alternatives such as rifampicin or fluoroquinolones may be used when resistance occurs, but isoniazid remains preferred for its potency, oral administration, and cost‑effectiveness in susceptible strains.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Isoniazida Labesfal is taken orally, usually once daily on an empty stomach to improve absorption. Patients should swallow the tablet with a full glass of water and follow the prescribing clinician’s instructions regarding timing relative to meals and other medications.

The most serious adverse events include severe hepatitis, which may present with jaundice and abdominal pain, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis. Prompt medical evaluation is essential if these symptoms occur during therapy.

Individuals with known hypersensitivity to isoniazid or any excipients, patients with pre‑existing severe liver disease, and those with certain metabolic deficiencies (e.g., severe G6PD deficiency) should avoid the medication unless a specialist determines that benefits outweigh risks.